Name: Compounded Mounjaro — Tirzepatide From $379/mo
Brand: SlimVault
Availability: InStock

About This Medication

WHAT IS MOUNJARO?

Mounjaro is the brand name for tirzepatide, a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist developed by Eli Lilly. FDA-approved in May 2022 for type 2 diabetes, it has rapidly become the most prescribed new weight-loss medication in the United States — largely due to its superior efficacy over semaglutide in head-to-head clinical trials.

Unlike semaglutide which only activates GLP-1 receptors, tirzepatide activates both GIP and GLP-1 receptors simultaneously. GIP receptors are expressed throughout the body including fat tissue, muscle, and the central nervous system. This dual action creates a more powerful and complementary appetite-suppressing and metabolic effect than a single receptor approach alone.

In the SURMOUNT-1 trial, patients on 15mg tirzepatide lost an average of 22.5% of their body weight over 72 weeks — the highest weight loss ever recorded for an FDA-approved non-surgical intervention. In the direct head-to-head SURMOUNT-5 trial (2025), tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide 2.4mg.

22.5%

Average body weight loss at 15mg in SURMOUNT-1 trial over 72 weeks

15mg

Maximum weekly dose — reached after approximately 20 weeks

2×

Hormone receptors targeted — GIP and GLP-1 simultaneously

60%

Of patients at 10–15mg lost 20%+ of body weight in trials

Mechanism of Action

WHY TIRZEPATIDE OUTPERFORMS SEMAGLUTIDE

The dual mechanism is what makes tirzepatide categorically different from semaglutide. While both drugs suppress appetite and slow gastric emptying through GLP-1 receptor activation, tirzepatide adds GIP receptor agonism — creating additional pathways for fat reduction and metabolic improvement that semaglutide simply cannot access.

🧬

GLP-1 Receptor Activation

Reduces appetite by activating receptors in the brain's satiety center, stimulates insulin release, and slows gastric emptying. Shared mechanism with Ozempic/Wegovy.

⚡

GIP Receptor Activation

Unique to tirzepatide. GIP receptors in fat tissue improve how the body uses and stores fat. Reduces fat accumulation and may enhance fat burning. Complements GLP-1 action for greater total effect.

🔥

Enhanced Thermogenesis

The dual action of tirzepatide appears to increase the body's resting metabolic rate more effectively than GLP-1 alone, contributing to greater calorie burn even at rest.

📉

Superior Insulin Sensitivity

In diabetic patients, tirzepatide produced HbA1c reductions of up to 2.3% — greater than any other approved diabetes medication. Improved insulin sensitivity drives better metabolic health alongside weight loss.

Complete Dosing Protocol

MOUNJARO TITRATION SCHEDULE

Tirzepatide follows a 6-step titration ladder from 2.5mg to a maximum of 15mg. Each step lasts a minimum of 4 weeks. The maintenance dose for weight loss is individualized — 5mg, 10mg, or 15mg — based on response and tolerance. Titration steps of 7.5mg and 12.5mg are stepping-stone doses and are not considered maintenance doses.

Step	Weeks	Dose	Notes
Initiation	Weeks 1–4	2.5mg	Tolerability dose only. Not a therapeutic dose. GI side effects are most pronounced here. Eat small, bland meals around injection day.
Step 2	Weeks 5–8	5mg	First maintenance-eligible dose. In SURMOUNT-1, patients at 5mg achieved 16% average weight loss over 72 weeks. Many patients are satisfied at this level.
Step 3	Weeks 9–12	7.5mg	Escalation step. Not a maintenance dose. Used to bridge toward 10mg. Significant appetite suppression at this level for most patients.
Maintenance	Week 13+	10mg	Primary maintenance dose for most patients. Trial data: average 21.4% body weight loss at 72 weeks. Strong efficacy with manageable side effects.
Step 5	Week 17+ (if needed)	12.5mg	Stepping-stone toward 15mg. Increase only if 10mg is tolerated and additional weight loss is desired.
Maximum	Week 21+	15mg	Maximum approved dose. 22.5% average weight loss in trials. 60% of patients at this dose lost 20%+ of body weight over 72 weeks.

Safety Information

SIDE EFFECTS

Common Side Effects Usually temporary

Nausea — affects 17–22% of patients in clinical trials. Most pronounced during dose increases. Eating small, low-fat meals reduces severity significantly.
Diarrhea — affects 13–16% of patients. Typically resolves within 4–8 weeks at a stable dose.
Vomiting — affects 6–10% of patients. Contact your provider if vomiting prevents hydration.
Decreased appetite — the desired therapeutic effect for weight loss.
Constipation — can alternate with diarrhea, especially in early weeks.
Indigestion — related to slowed gastric emptying. Avoid heavy or fatty meals around injection day.
Injection site reactions — mild redness or bruising at the injection site.
Fatigue — especially on injection day and the following day in early titration.

Serious Side Effects Rare — seek care immediately

Thyroid C-cell tumors — tirzepatide carries an FDA boxed warning based on animal studies. Do not use if you have a personal or family history of medullary thyroid carcinoma or MEN 2.
Pancreatitis — severe upper abdominal pain radiating to the back. Discontinue immediately. Seek emergency care.
Acute kidney injury — secondary to dehydration from GI side effects. Stay well hydrated, especially during dose increases.
Gallbladder disease — gallstones and cholecystitis have been reported. Symptoms: right upper abdominal pain, fever, jaundice.
Hypoglycemia — risk increases when combined with insulin or sulfonylurea medications.
Anaphylaxis or angioedema — rare but serious allergic reaction. Seek emergency treatment.
Intestinal obstruction — extremely rare. Report severe abdominal pain with bloating and inability to pass gas or stool.

⛔ Contraindications

Do not use tirzepatide if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not combine with other GLP-1 receptor agonists, other tirzepatide products, or Ozempic/Wegovy simultaneously. Not for use during pregnancy — may cause fetal harm. Oral contraceptives may be less effective while taking tirzepatide due to delayed gastric emptying — use backup contraception for the first 4 weeks after each dose increase.

Customer Experiences

REVIEWS

4.9

★★★★★

Based on 389 verified orders

★★★★★

"I switched from Ozempic to Mounjaro after hitting a plateau at 2mg. The difference was dramatic. In 3 months on Mounjaro 10mg I've lost more than I did in 6 months on Ozempic. Food simply does not appeal to me anymore."

Christine L.

Mounjaro 10mg · 3 Months

★★★★★

"41 pounds in 5 months. I've never lost weight this fast without feeling starved. On Mounjaro I feel satisfied all day eating half portions. My doctor is amazed. The compounded version is identical in effect at a fraction of the price."

Rachel B.

Mounjaro 15mg · 5 Months

★★★★★

"The nausea week 1 was manageable — just felt off for 2 days. By week 3 nothing. Now at 7.5mg and the weight is falling off. Ordered the elite bundle for 3 months and saved an extra $138. Highly recommend."

Tamara W.

Mounjaro 7.5mg · Elite Bundle

Questions Answered

MOUNJARO FAQ

Is Mounjaro better than Ozempic for weight loss? +

Yes, based on head-to-head clinical trial data. In the SURMOUNT-5 trial (2025), tirzepatide produced 20.2% average weight loss versus 13.7% for semaglutide 2.4mg — a clinically meaningful difference. Mounjaro's dual GIP/GLP-1 mechanism gives it a pharmacological advantage for weight reduction specifically. However, individual responses vary, and some patients tolerate semaglutide better than tirzepatide.

What is the difference between Mounjaro and Zepbound? +

Mounjaro and Zepbound are the same molecule (tirzepatide) from the same manufacturer (Eli Lilly). Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea. The titration schedule and dose options are identical. The only differences are the indication label and the brand packaging. Our compounded tirzepatide applies to both use cases.

What dose should I start at if I've been on Ozempic? +

Even if you have previous experience with semaglutide, you must start tirzepatide at 2.5mg. The molecules are different and your tolerance to one does not transfer to the other. Always begin at the initiation dose and follow the full titration schedule regardless of prior GLP-1 experience.

Do I need to reach 15mg to get results? +

No. Significant weight loss occurs at every maintenance dose level. In SURMOUNT-1, patients at 5mg averaged 16% weight loss over 72 weeks; at 10mg, 21.4%; and at 15mg, 22.5%. Many patients achieve excellent results at 5mg or 10mg without ever reaching the maximum dose. The goal is to find the lowest dose that delivers satisfactory weight loss with manageable side effects.

How long until I see results on Mounjaro? +

Appetite suppression typically begins during the first 2–3 weeks. Measurable weight loss usually starts around week 4–6. By month 3 (typically at 7.5–10mg), most patients have lost 10–15% of starting weight. Maximum results are seen at 72 weeks in clinical trials, though meaningful transformation is evident much earlier.

Related Medications

MOUNJARO

WHAT IS MOUNJARO?

WHY TIRZEPATIDE OUTPERFORMS SEMAGLUTIDE

MOUNJARO TITRATION SCHEDULE

SIDE EFFECTS

REVIEWS

MOUNJARO FAQ

YOU MAY ALSO CONSIDER